AVAlessandra Vitaliti

Alessandra Vitaliti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandra Vitaliti has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DNA-decorated phase-shift microdroplets enable programmable coalescence and gene transfection

    by Giulia Perilli, Angela Ditri, Alessandra Vitaliti, Yosra Toumia, Alessandro Porchetta, Gaio Paradossi, Fabio Domenici

    Hypothesis. Phase-shift perfluorocarbon microdroplets (MDs) are a promising and flexible method for challenging applications in colloid science, such as customizing chemical reactions or enhancing tumor gene delivery efficiency. To achieve these goals, we focused on stable MDs made of a decafluoropentane core and a dimethyldioctadecylammonium bromide (DDAB) lipid shell that binds DNA through electrostatic interactions to create DNA-MDs assemblies.Experimental. The MDs were obtained via ultrasound homogenization and decorated with complementary DNAs. Fluorescence, confocal microscopy, and dynamic light scattering methodologies were combined to measure the binding features driving DNA-MDs formation and their coalescing interactions. The effect of the DNA-MDs at the cell interface was evaluated by MTT viability assay and DNA transfection in tumor melanoma cells.Findings. We defined the colloidal formulation of DNA-MDs, functional for both chemical and biomedical relevant applications. First, we identified the conditions that enable DNA-MDs to rapidly and selectively coalesce via oligonucleotide hybridization at the MDs interface. Then, we used DNA-MDs to efficiently enter nucleic acids into human melanoma cells, even within a two-step transfection protocol to promote intracellular DNA strand displacement.Our results could shed new light on conducting controlled reactions in small volumes, realizing microreactors, as well as designing consensus gene transfection strategies.

  • Open Access

    Intra-Arterial Super-Selective Delivery of Yttrium-90 for the Treatment of Recurrent Glioblastoma: In Silico Proof of Concept with Feasibility and Safety Analysis

    by Giulia Paolani, Silvia Minosse, Silvia Strolin, Miriam Santoro, Noemi Pucci, Francesca Di Giuliano, Francesco Garaci, Letizia Oddo, Yosra Toumia, Eugenia Guida, et al.

    Background: Intra-arterial cerebral infusion (IACI) of radiotherapeutics is a promising treatment for glioblastoma (GBM) recurrence. We investigated the in silico feasibility and safety of Yttrium-90-Poly(vinyl alcohol)-Microbubble (90Y-PVA-MB) IACI in patients with recurrent GBM and compared the results with those of external beam radiation therapy (EBRT). Methods: Contrast-enhanced T1-weighted magnetic resonance imaging (T1W-MRI) was used to delineate the tumor volumes and CT scans were used to automatically segment the organs at risk in nine patients with recurrent GBM. Volumetric Modulated Arc Therapy (VMAT) treatment plans were generated using a clinical treatment planning system. Assuming the relative intensity of each voxel from the MR-T1W as a valid surrogate for the post-IACI 90Y-PVA-MB distribution, a specific 90Y dose voxel kernel was obtained through Monte Carlo (MC) simulations and convolved with the MRI, resulting in a 90Y-PVA-MB-based dose distribution that was then compared with the VMAT plans. Results: The physical dose distribution obtained from the simulation of 1GBq of 90Y-PVA-MBs was rescaled to ensure that 95% of the prescribed dose was delivered to 95% or 99% of the target (i.e., A95% and A99%, respectively). The calculated activities were A95% = 269.2 [63.6–2334.1] MBq and A99% = 370.6 [93.8–3315.2] MBq, while the mean doses to the target were 58.2 [58.0–60.0] Gy for VMAT, and 123.1 [106.9–153.9] Gy and 170.1 [145.9–223.8] Gy for A95% and A99%, respectively. Additionally, non-target brain tissue was spared in the 90Y-PVA-MB treatment compared to the VMAT approach, with a median [range] of mean doses of 12.5 [12.0–23.0] Gy for VMAT, and 0.6 [0.2–1.0] Gy and 0.9 [0.3–1.5] Gy for the 90Y treatments assuming A95% and A99%, respectively. Conclusions: 90Y-PVA-MB IACI using MR-T1W appears to be feasible and safe, as it enables the delivery of higher doses to tumors and lower doses to non-target volumes compared to the VMAT approach.


  • Open Access

    Integration of single-cell datasets depicts profiles of macrophages and fibro/adipogenic progenitors in dystrophic muscle

    by Alessandra Vitaliti, Alessio Reggio, Marta Colletti, Angela Galardi, Alessandro Palma


  • Open Access

    Copper-Dependent Kinases and Their Role in Cancer Inception, Progression and Metastasis

    by Alessandra Vitaliti, Anastasia De Luca, Luisa Rossi

    In recent years, copper function has been expanded beyond its consolidated role as a cofactor of enzyme catalysis. Recent papers have demonstrated a new dynamic role for copper in the regulation of cell signaling pathways through direct interaction with protein kinases, modulating their activity. The activation of these pathways is exacerbated in cancer cells to sustain the different steps of tumor growth and dissemination. This review will focus on a novel proposed role for the transition metal copper as a regulator of cell signaling pathways through direct interaction with known protein kinases, which exhibit binding domains for this metal. Activation of these pathways in cancer cells supports both tumor growth and dissemination. In addition to the description of the results recently reported in the literature on the subject, relevance will be given to the possibility of controlling the cellular levels of copper and its homeostatic regulators. Overall, these findings may be of central relevance in order to propose copper and its homeostatic regulators as possible targets for novel therapies, which may act synergistically to those already existing to control cancer growth and dissemination.


  • Open Access

    SSADH Variants Increase Susceptibility of U87 Cells to Mitochondrial Pro-Oxidant Insult

    by Giovanna Menduti, Alessandra Vitaliti, Concetta Rosa Capo, Daniele Lettieri-Barbato, Katia Aquilano, Patrizia Malaspina, Luisa Rossi

    Succinate semialdehyde dehydrogenase (SSADH) is a mitochondrial enzyme, encoded by ALDH5A1, mainly involved in γ-aminobutyric acid (GABA) catabolism and energy supply of neuronal cells, possibly contributing to antioxidant defense. This study aimed to further investigate the antioxidant role of SSADH, and to verify if common SNPs of ALDH5A1 may affect SSADH activity, stability, and mitochondrial function. In this study, we used U87 glioblastoma cells as they represent a glial cell line. These cells were transiently transfected with a cDNA construct simultaneously harboring three SNPs encoding for a triple mutant (TM) SSADH protein (p.G36R/p.H180Y/p.P182L) or with wild type (WT) cDNA. SSADH activity and protein level were measured. Cell viability, lipid peroxidation, mitochondrial morphology, membrane potential (ΔΨ), and protein markers of mitochondrial stress were evaluated upon Paraquat treatment, in TM and WT transfected cells. TM transfected cells show lower SSADH protein content and activity, fragmented mitochondria, higher levels of peroxidized lipids, and altered ΔΨ than WT transfected cells. Upon Paraquat treatment, TM cells show higher cell death, lipid peroxidation, 4-HNE protein adducts, and lower ΔΨ, than WT transfected cells. These results reinforce the hypothesis that SSADH contributes to cellular antioxidant defense; furthermore, common SNPs may produce unstable, less active SSADH, which could per se negatively affect mitochondrial function and, under oxidative stress conditions, fail to protect mitochondria.


  • Validation—The Key to Translatable Cytometry in the 21st Century

    by Virginia Litwin, Cherie Green, Alessandra Vitaliti